FDA To Consider Critical Path Trial Design Proposals On Case-By-Case Basis
Executive Summary
FDA will generally take a case-by-case approach to considering and accepting development programs using clinical trial designs discussed in its Critical Path opportunities list
You may also be interested in...
Personalized Medicine Is Closer Than You Think, FDA’s Throckmorton Says
Personalized medicine should be adopted as a prospective strategy in drug development rather than primarily serving as a tool to salvage failing drug candidates, participants at FDA's Science Forum suggested
Personalized Medicine Is Closer Than You Think, FDA’s Throckmorton Says
Personalized medicine should be adopted as a prospective strategy in drug development rather than primarily serving as a tool to salvage failing drug candidates, participants at FDA's Science Forum suggested
Use Of Non-Inferiority Trials Could Increase Despite Unclear Guidance
Regulators need to provide greater clarity on non-inferiority clinical trial designs, an Amgen exec said during FDA's 2006 Science Forum